Drug intelligence / Profile preview

ronacaleret

Development stage: Discontinued
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

Ronacaleret is an orally administered small molecule that acts as a calcium-sensing receptor antagonist (calcilytic). By antagonizing the calcium-sensing receptor (CaSR) on the surface of parathyroid gland cells, it stimulates endogenous parathyroid hormone release, which can increase bone mineral density. Ronacaleret was developed primarily for the treatment of postmenopausal osteoporosis and has also been investigated for stem cell mobilization. The drug reached up to phase II clinical trials but development was discontinued for all known indications. It was co-developed by NPS Pharmaceuticals and GlaxoSmithKline[1][2][3][4][5].

Other names: ronacaleret hydrochloride

Targets

CaSR (Extracellular calcium-sensing receptor)

Beyond the preview

Go deeper on ronacaleret.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ronacaleret.

Explore the full profile